Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GYRE Stock Forecast 2026-2027
$7.90
Current Price
$761.03M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GYRE Price Targets
+153.2%
To High Target of $20.00
+127.8%
To Median Target of $18.00
+127.8%
To Low Target of $18.00
GYRE Price Momentum
+6.9%
1 Week Change
+3.3%
1 Month Change
-11.0%
1 Year Change
+11.9%
Year-to-Date Change
-32.9%
From 52W High of $11.78
+20.2%
From 52W Low of $6.57
📊 TOP ANALYST CALLS
Did GYRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Gyre Therapeutics is one of their latest high-conviction picks.
Latest GYRE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, GYRE has a bullish consensus with a median price target of $18.00 (ranging from $18.00 to $20.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.90, the median forecast implies a 127.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Keller at HC Wainwright & Co., suggesting a 127.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GYRE Analyst Ratings
3
Buy
0
Hold
0
Sell
GYRE Price Target Range
Low
$18.00
Average
$18.00
High
$20.00
Current: $7.90
Latest GYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GYRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2025 | Jefferies | Roger Song | Buy | Initiates | $16.00 |
| Aug 26, 2025 | HC Wainwright & Co. | Matthew Keller | Buy | Initiates | $18.00 |
Gyre Therapeutics Inc. (GYRE) Competitors
The following stocks are similar to Gyre Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gyre Therapeutics Inc. (GYRE) Financial Data
Gyre Therapeutics Inc. has a market capitalization of $761.03M with a P/E ratio of 392.0x. The company generates $116.59M in trailing twelve-month revenue with a 4.3% profit margin.
Revenue growth is +33.4% quarter-over-quarter, while maintaining an operating margin of +0.3% and return on equity of +8.2%.
Valuation Metrics
Market Cap
$761.03M
Enterprise Value
$700.67M
P/E Ratio
392.0x
PEG Ratio
0.0x
Price/Sales
6.5x
Growth & Margins
Revenue Growth (YoY)
+33.4%
Gross Margin
+95.3%
Operating Margin
+0.3%
Net Margin
+4.3%
EPS Growth
+33.4%
Financial Health
Cash/Price Ratio
+7.3%
Current Ratio
5.6x
Debt/Equity
0.7x
ROE
+8.2%
ROA
+4.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Gyre Therapeutics Inc. (GYRE) Business Model
About Gyre Therapeutics Inc.
What They Do
Biotechnology firm developing innovative therapies.
Business Model
Gyre Therapeutics generates revenue through the development and commercialization of therapeutic products targeting unmet medical needs. The company employs a robust pipeline strategy that combines in-house research and development with collaborative partnerships, which helps accelerate drug development and clinical trials.
Additional Information
The firm focuses on complex diseases in areas such as oncology, neurology, and rare genetic disorders. By forming strategic alliances with academic institutions and pharmaceutical companies, Gyre Therapeutics enhances its scientific capabilities and expands its therapeutic portfolio, positioning itself as a key player in advancing medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
579
CEO
Dr. Han Ying Ph.D.
Country
United States
IPO Year
2006
Website
www.gyretx.comGyre Therapeutics Inc. (GYRE) Latest News & Analysis
Latest News
Quick Summary
Gyre Therapeutics (Nasdaq: GYRE) received priority review status from China's CDE for its NDA of Hydronidone (F351) to treat chronic hepatitis B-induced liver fibrosis, marking a key milestone.
Why It Matters
Gyre Therapeutics receiving priority review for Hydronidone in China could accelerate market entry, potentially boosting revenue and stock value amid growing demand for hepatitis B treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Gyre Therapeutics reported 2025 revenue of $116.6M, up 10% YoY. It projects 2026 revenue of $100.5-111.0M and plans to acquire Cullgen. NDA for Hydronidone submission expected in H1 2026.
Why It Matters
Gyre Therapeutics' revenue growth and strategic acquisition signal potential expansion. Regulatory advancements for Hydronidone could lead to market opportunities, impacting future earnings and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gyre Therapeutics, Inc. (GYRE) reported Q3 earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08. This is an increase from $0.01 per share in the same quarter last year.
Why It Matters
Gyre Therapeutics' earnings miss signals potential operational issues, which could impact investor confidence and affect stock performance. Comparisons to last year's earnings show growth, but not meeting estimates may raise concerns.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
A new acquisition will form a fully integrated U.S. and China biopharmaceutical company, focusing on inflammatory diseases and cancers, with revenue assets and a degrader-antibody conjugates platform.
Why It Matters
The acquisition enhances growth potential by combining assets and technology, positioning the company competitively in lucrative biopharmaceutical markets, especially for treating cancers and inflammatory diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Gyre Pharmaceuticals plans to file a New Drug Application for Hydronidone in China by mid-2026, following a positive Pre-NDA meeting regarding existing Phase 3 data.
Why It Matters
Gyre Pharmaceuticals' progress towards conditional approval for Hydronidone in China signals potential revenue growth and market entry, influencing stock valuations and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
5 months ago
Quick Summary
For Q3 2025, net income was $5.9 million, with a 20% revenue increase to $30.6 million. Full-year revenue guidance is revised to $115-118 million due to rollout delays.
Why It Matters
Revised revenue guidance and delayed product rollout raise concerns about future earnings. However, strong quarterly growth and improved net income indicate positive operational performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GYRE Stock
What is Gyre Therapeutics Inc.'s (GYRE) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Gyre Therapeutics Inc. (GYRE) has a median price target of $18.00. The highest price target is $20.00 and the lowest is $18.00.
Is GYRE stock a good investment in 2026?
According to current analyst ratings, GYRE has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GYRE stock?
Wall Street analysts predict GYRE stock could reach $18.00 in the next 12 months. This represents a 127.8% increase from the current price of $7.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Gyre Therapeutics Inc.'s business model?
Gyre Therapeutics generates revenue through the development and commercialization of therapeutic products targeting unmet medical needs. The company employs a robust pipeline strategy that combines in-house research and development with collaborative partnerships, which helps accelerate drug development and clinical trials.
What is the highest forecasted price for GYRE Gyre Therapeutics Inc.?
The highest price target for GYRE is $20.00 from at , which represents a 153.2% increase from the current price of $7.90.
What is the lowest forecasted price for GYRE Gyre Therapeutics Inc.?
The lowest price target for GYRE is $18.00 from Matthew Keller at HC Wainwright & Co., which represents a 127.8% increase from the current price of $7.90.
What is the overall GYRE consensus from analysts for Gyre Therapeutics Inc.?
The overall analyst consensus for GYRE is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are GYRE stock price projections?
Stock price projections, including those for Gyre Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 6:06 AM UTC